Cystic Fibrosis Therapeutics Market Report by Drug Class (Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), Bronchodilators, Mucolytic, Pancreatic Enzyme Supplement , and Others), Route of Administration (Oral Drugs, and Inhaled Drugs), Distribution Channel (Hospitals, Retail Pharmacies, and Others), Regions and Company Analysis 2024-2032

Cystic Fibrosis Therapeutics Market Analysis

The Cystic Fibrosis Therapeutics Market size is projected to obtain US$ 15.42 Billion by 2032 from US$ 7.07 Billion in 2023, with a CAGR of 9.05% from 2024–2032.

Cystic Fibrosis is a famous genetic disease cause by mutations inside the CFTR gene. It impacts the lungs and digestive device via interfering with the CFTR ion channel's function, which regulates flow throughout the cell membrane. The CFTR gene is located on chromosome 7, and this situation influences diverse organ systems worldwide, with over 30,000 individuals within the US alone and a worldwide incidence exceeding 70,000. The signs and symptoms might also include coughing, wheezing, shortness of breath, digestive issues, and poor growth. However, with appropriate medication, therapy, and life adjustments, it is feasible to manage this circumstance efficiently. While there's no therapy but, huge studies and improvement are underway to discover an everlasting strategy to this debilitating health situation.

In March 2024, The Cystic Fibrosis Foundation committed over US$ 6.6 Million in additional investment to Sionna Therapeutics, assisting ongoing research into new modulator recovery methods. These advancements preserve promise for imparting opportunity remedies to those currently to be had.

Number of people living worldwide with Cystic Fibrosis

According to a document from The Cystic Fibrosis (CF) Foundation, the wide variety of people suffering from Cystic Fibrosis has increased. In 2022, over 105,000 human beings had been diagnosed with the state of affairs, with nearly 40,000 being from USA.

In 2022, over 11,000 human beings with CF registered on the United Kingdom CF Registry for the first time.

In April 2024, Cystic Fibrosis (CF) will stay the maximum common genetically inherited sickness, with early onset and high mortality costs. Germany reports approximately one affected new baby in every of 2,500 births. The presence of 6,776 sufferers and 87 CF centers inside the German Cystic Fibrosis Registry underscores the significance of this situation.
The CF Registry 2022 consists of data on 1636 Dutch human beings with CF.

Cystic Fibrosis (CF) is gaining recognition in China, with the form of stated patients inside the past decade surpassing 2.5 times in the overall in the previous 30 years. The predicted fashionable amount of CF patients in China now exceeds 20,000.

Feb 2023, In India, patients’ families estimate the kind of identified people residing with CF to be 600–1200.

United States Cystic Fibrosis Therapeutics Market

The North American location considerably contributes to the worldwide cystic fibrosis capsules marketplace and is witnessing steady growth. In the US, maximum of the people laid low with cystic fibrosis are of Caucasian descent. The growing incidence of cystic fibrosis in USA has brought about multiplied authorities’ initiatives to improve healthcare services, boost studies and improvement tasks, and decorate the supply of cystic fibrosis capsules inside the market. For instance, the United States Cystic Fibrosis Foundation has mounted an educational discussion board for cystic fibrosis experts to share the present-day traits in studies and improvement related to cystic fibrosis therapeutics.

Furthermore, the nicely established up healthcare infrastructure, distinguished marketplace leaders, and favorable repayment rules within the United States are anticipated to propel the demand for cystic fibrosis tablets in the united states over the forecast period. Additionally, the increasing investments via fundamental pharmaceutical businesses in progressive drug development programs, consisting of gene remedy, are anticipated to contribute to the boom of the cystic fibrosis pills marketplace in U.S.

Cystic Fibrosis Therapeutics Key Player Analysis

Prominent players driving the Cystic Fibrosis therapeutics market include Vertex Pharmaceuticals, Abbvie Inc., Novartis Ag, Gilead Sciences, Viatris INC, Pfizer, AstraZeneca, and F. Hoffmann-La Roche Ltd.

Global Cystic Fibrosis Therapeutics Company News

• The CF Foundation invested US$ 15 Million in ReCode Therapeutics in Jan 2023. ReCode specializes in growing advanced shipping methods for mRNA and gene correction therapeutics, primarily focusing on an inhaled mRNA-based totally remedy for Cystic Fibrosis.
• Dec 2022, Vertex Pharmaceuticals acquired FDA clearance for VX-522, an mRNA treatment for CF lung disease. A clinical trial for CF sufferers is expected soon.
• In August 2021, Sanofi acquired Translate Bio for US$ 3.2 Billion. Translate Bio specializes in developing drugs for cystic Fibrosis and rare pulmonary diseases.
• In Nov 2021, Eloxx Pharma introduced a Phase 2 medical trial of ELX-02 in CF Class 1.
• In October 2020, Roche and Abbvie obtained the product portfolio for TMEM 16A to decorate their product variety.
• In November 2020, Polyphor reached a deal with the Cystic Fibrosis Foundation to develop inhaled murepavadin for CF patients.
• In December 2020, Researchers at Hopkins University and Medicine developed a new antibiotic to combat drug-resistant pathogens like Mycobacterium abscesses, which can damage humans with cystic Fibrosis or lung sicknesses.
• In April 2019, The FDA authorized KALYDECO by using Vertex Pharmaceuticals. This expands treatment alternatives for children with cystic Fibrosis as young as six months old, probably changing the disease's progression.

Drug Class

1.    Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
2.    Bronchodilators
3.    Mucolytic
4.    Pancreatic Enzyme Supplement
5.    Others

Route of Administration

1.    Oral Drugs
2.    Inhaled Drugs

Distribution Channel

1.    Hospitals
2.    Retail Pharmacies
3.    Others

Countries

1.    North America

1.1    United States
1.2    Canada

2.    Europe

2.1    France
2.2    Germany
2.3    Italy
2.4    Spain
2.5    United Kingdom
2.6    Belgium
2.7    Netherland
2.8    Turkey

3.    Asia Pacific

3.1    China
3.2    Japan
3.3    India
3.4    South Korea
3.5    Thailand
3.6    Malaysia
3.7    Indonesia
3.8    Australia
3.9    New Zealand

4.    Latin America

4.1    Brazil
4.2    Mexico
4.3    Argentina

5.    Middle East & Africa

5.1    Saudi Arabia
5.2    UAE
5.3    South Africa

All the Key players have been covered from 4 Viewpoints:

•    Business overview
•    Recent Development
•    SWOT Analysis
•    Revenue Analysis

Key Players Analysis

1.    Vertex Pharmaceuticals
2.    Abbvie Inc.
3.    Novartis Ag
4.    Gilead Sciences
5.    Viatris INC
6.    Pfizer
7.    Astrazeneca
8.    F. Hoffmann-La Roche Ltd

Report Details: